OncoMatch

OncoMatch/Clinical Trials/NCT05892393

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Is NCT05892393 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Zirconium Zr 89-DFO-YS5 for multiple myeloma.

Phase 1RecruitingRobert Flavell, MD, PhDNCT05892393Data as of Jun 2026

Treatment: Zirconium Zr 89-DFO-YS5This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Zirconium Zr 89-DFO-YS5

Cancer type

Multiple Myeloma

Lab requirements

Kidney function

Creatinine clearance >= 60 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine <= 1.5x the institutional upper limit of normal

Liver function

Total bilirubin <= 1.5 X institutional upper limit of normal (ULN); AST <= 3 X ULN; ALT <= 3 X ULN

Total bilirubin <= 1.5 X institutional upper limit of normal (ULN); AST <= 3 X ULN; ALT <= 3 X ULN; Creatinine clearance >= 60 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine <= 1.5x the institutional upper limit of normal.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of California, San Francisco · San Francisco, California

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05892393 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify